Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Bumper pay for Viatris boss

Posted 5 May 2021

Mylan's long-time heavy hitter Robert Coury, now the executive chairman at Viatris scored US$29.06 million in total compensation last year for executing the merger with Pfizer's UpJohn unit during the midst of the pandemic. 

Coury began at Mylan in 1995 serving as a strategic advisor to the company before stepping into CEO from 2002 to 2012. He served as executive chairman from 2012 until he became chairman in 2016.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended